Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies. (October 2022) - Kindler, H.; Harvey, R.D.; Duska, L.R.; Gandhi, L.; Sullivan, R.J.; Gastinne, T.; Kwiatek, M.; García-Sancho, A.M.; Hadar, N.; Kann, L.; Faulhaber, N.; Drescher, C.